NCT07773428

Brief Summary

Treatment selection for refractory radicular low back pain is frequently made in the absence of direct comparative evidence between competing minimally invasive options. By placing ozone therapy and PRF side by side within a single clinical service and following patients for six months, this study contributes pragmatic evidence that maps more closely onto everyday decision-making than isolated single-arm reports. The findings carry practical implications for clinicians, patients, and health systems. For clinicians, a clearer understanding of which modality offers more sustained pain relief can inform first-line selection and patient counseling. For patients, improved durability of benefit translates directly into better quality of life, reduced reliance on systemic analgesics, and a lower likelihood of progressing to surgery. For resource-constrained health systems, evidence favoring a lower-cost, well-tolerated, outpatient procedure has clear value for service planning and cost-effectiveness. Finally, by reporting outcomes transparently-including instances where between-group differences did not survive statistical adjustment-this study aims to add measured, reliable evidence to a literature that has at times been limited by small samples, heterogeneous protocols, and short follow-up.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
69

participants targeted

Target at P50-P75 for not_applicable low-back-pain

Timeline
Completed

Started Jul 2026

Shorter than P25 for not_applicable low-back-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2026

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

August 14, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 19, 2026

Completed
Last Updated

August 19, 2026

Status Verified

August 1, 2026

Enrollment Period

1 month

First QC Date

August 14, 2026

Last Update Submit

August 14, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • pain intensity

    measured with the Visual Analog Scale at baseline and at 1,3, and 6 months

    6 months

  • functional disability

    measured with the Oswestry Disability Index at baseline and at 1,3, and 6 months

    6 months

Secondary Outcomes (1)

  • Procedure-related complications

    6 months

Study Arms (2)

Intradiscal ozone therapy

ACTIVE COMPARATOR
Procedure: Intradiscal ozone therapy

Pulsed radiofrequency

ACTIVE COMPARATOR
Procedure: Pulsed radiofrequency

Interventions

Antibiotic prophylaxis was administered with cefazolin 1 g intravenously over 15 minutes, approximately one hour before the procedure. Under fluoroscopic guidance, a 22-gauge, 15-cm Chiba needle was advanced into the target intervertebral disc, and intradiscal placement was confirmed by contrast injection, demonstrating satisfactory spread. Ozone 5 mL at a concentration of 30 µg/mL was injected intradiscally. The needle was then repositioned to the inferior neural foramen (Kambin's triangle); contrast injection confirmed appropriate spread without vascular uptake, and a further 5 mL of ozone at 30 µg/mL was administered into the foraminal/perineural region.

Intradiscal ozone therapy

Under fluoroscopic guidance, a radiofrequency needle was advanced to the target safe (supraneural) triangle adjacent to the affected dorsal root ganglion. Correct placement was confirmed in anteroposterior and lateral views, and contrast injection demonstrated appropriate epidural/perineural spread without vascular uptake. Pulsed radiofrequency was applied at 42 °C for 6 minutes, with impedance maintained between 300 and 500 Ω. Following PRF, 3 mL of a mixture containing 40 mg methylprednisolone with lidocaine was injected into the foraminal region.

Pulsed radiofrequency

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age greater than 18 years.
  • Low back and leg pain of more than six weeks' duration.
  • Failure to respond to conservative management.
  • Grade I-IV disc pathology.
  • Unilateral leg pain.
  • Three or fewer spinal levels are involved.

You may not qualify if:

  • Severe canal or foraminal stenosis.
  • Severely dehydrated disc.
  • Allergy to antibiotics or contrast media.
  • Previous spine surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nizwa Hospital

Nizwa, AL Radah State, 611, Oman

Location

Related Publications (2)

  • Strand NH, Hagedorn JM, Dunn T, Johnson B, Abd-Elsayed A, Covington S, Freeman J, Dawodu A, Maloney J. Advances in radiofrequency ablation: mechanism of action and technology. Ann Palliat Med. 2024 Jul;13(4):1028-1034. doi: 10.21037/apm-23-457. Epub 2024 Jul 18.

    PMID: 39043563BACKGROUND
  • Sam J, Catapano M, Sahni S, Ma F, Abd-Elsayed A, Visnjevac O. Pulsed Radiofrequency in Interventional Pain Management: Cellular and Molecular Mechanisms of Action - An Update and Review. Pain Physician. 2021 Dec;24(8):525-532.

    PMID: 34793641BACKGROUND

MeSH Terms

Conditions

Low Back PainRadiculopathy

Interventions

Pulsed Radiofrequency Treatment

Condition Hierarchy (Ancestors)

Back PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRadiofrequency TherapyRehabilitation

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 14, 2026

First Posted

August 19, 2026

Study Start

July 1, 2026

Primary Completion

August 1, 2026

Study Completion

August 1, 2026

Last Updated

August 19, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will share

The datasets used and/or analyzed during the current study are available from the principal investigator upon reasonable request.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
6 months after study publication
Access Criteria
by email

Locations